If you’re eyeing Biotest and wondering whether now is the right moment to buy, hold, or move on, you’re in good company. The stock has been resting at €28.4, and though its short-term moves have been muted with a 0.0% change over both the past week and month, a look at the bigger picture is more revealing. This year alone, Biotest has ticked up by 4.4%, and it has scratched out a nearly 5% gain over the past twelve months. Those numbers might seem modest, especially when you notice that the stock is still down 19% compared to three years ago. Yet, step back to the five-year view and Biotest has managed a healthy 13.9% return, showing that long-term resilience is part of its DNA.

Much of this steady performance follows broader market forces, including shifts in biotech sentiment and ongoing developments in the healthcare sector. Biotest remains an active player in this space. If you’re weighing Biotest’s true potential, valuation is where things get interesting. On our valuation scale, Biotest scores a 2 out of 6, meaning it appears undervalued in two key checks but falls short in the other four. However, not all valuation measures are created equal. Here is a breakdown of the main approaches to see if the numbers stack up for Biotest, and read on for what we consider an even smarter lens on company value at the end.

Biotest scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

The Dividend Discount Model (DDM) is a valuation method that estimates a stock's intrinsic value by projecting future dividend payments and then discounting them back to their present value. This approach relies on the idea that a company's worth is ultimately based on the cash it returns to shareholders through dividends.

Looking at Biotest, the latest data shows an annual dividend per share (DPS) of €0.62. However, the company's return on equity stands at -2.76%, and the payout ratio is an unusual -1.48. These figures translate into an expected annual dividend growth rate of roughly -2.8%. This suggests not only that dividends are unlikely to grow but that there may be underlying challenges to dividend sustainability going forward.

Based on this DDM analysis, the estimated intrinsic value for Biotest's stock is just €8.22 per share. Compared to its current price of €28.40, this signals that the stock is significantly overvalued, with an implied overvaluation of approximately 246%.

Result: OVERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Biotest.

Our Dividend Discount Model (DDM) analysis suggests Biotest may be overvalued by 245.6%. Find undervalued stocks or create your own screener to find better value opportunities.

The Price-to-Sales (P/S) ratio is often used as a preferred valuation metric for companies that may not yet be profitable, such as many in the biotech sector. It helps investors assess what value the market places on each euro of a company’s revenue. This is especially helpful when traditional earnings-based measures like the Price-to-Earnings ratio are less meaningful or even negative.

Evaluating the “right” P/S ratio involves looking at growth prospects and risk. Fast-growing companies in an innovative industry may warrant higher multiples, while more stable, slower growers should generally trade at lower ratios. The riskier the outlook, the less investors are typically willing to pay for each euro in sales.

Biotest currently trades at a P/S ratio of 1.77x, which is considerably below both the biotech industry average of 11.10x and its peer group average of 23.80x. At first glance, this might suggest it is undervalued relative to the broader sector and competitors.

However, Simply Wall St calculates a proprietary “Fair Ratio” which considers more than just peer and industry averages. This Fair Ratio incorporates dynamics such as Biotest’s earnings growth, profit margins, risk profile, and market capitalization. The aim is to provide a more tailored benchmark than industry-wide comparisons alone can offer.

Because Simply Wall St's Fair Ratio looks at real company fundamentals, it avoids common pitfalls of rough comparisons. In Biotest’s case, the Fair Ratio precisely matches the actual P/S ratio. This indicates that the market price aligns closely with the company’s true value considering its specifics.

Result: ABOUT RIGHT

PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is your unique interpretation of a company’s future. It is the story you build behind the numbers, where you forecast Biotest’s future revenue, earnings, and margins, and then estimate what you think is a fair value for the stock.

Narratives connect your perspective on the company with a financial forecast, making it easy to see how your outlook translates into a fair value based on your own assumptions. This feature is simple to use and available on Simply Wall St’s Community page, where millions of investors already share, compare, and discuss their views.

With Narratives, you can decide whether to buy, hold, or sell Biotest by comparing your calculated fair value to today’s market price, while staying updated. Narratives automatically adjust when new information like fresh earnings or news is released.

For example, one investor might predict rapid growth and see Biotest’s fair value far above today’s price, while another might anticipate slowdowns and see it well below. This demonstrates how different stories can lead to very different investment decisions.

Do you think there's more to the story for Biotest? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BIO3.xtra.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com